Niagen Bioscience Q2 Revenue Misses, Profit Collapses as Costs Surge; Launches Pharma Program

summarizeSummary

Niagen Bioscience missed Q2 revenue estimates and saw profits collapse as ingredient sales slumped and marketing costs surged. The company also launched a pharmaceutical program and telehealth platform, but the near-term outlook remains pressured.

check_boxKey Events · Earnings and Guidance · NAGE

• Q2 Revenue Miss

  Net sales of $29.8 million missed the $30.7 million consensus, with Tru Niagen sales of $24.2 million and ingredient sales declining to $5.4 million from $7.4 million a year ago.

• Profit Collapse

  Net income fell to $1.0 million from $3.6 million in Q2 2025, driven by a 23% increase in sales and marketing expenses to $10.1 million. Adjusted EBITDA dropped to $3.0 million from $5.0 million.

• Strategic Launches

  Launched Niagen Plus telehealth platform and introduced NB4168, a lead pharmaceutical candidate for rare genetic diseases, receiving Rare Pediatric Disease and Orphan Drug designations.

• Cautious 2026 Outlook

  E-commerce expected to grow 10-15%, but ingredient business to decline further; Niagen Plus and skincare partnerships not expected to contribute meaningfully until 2027.

auto_awesomeAnalysis · NAGE · Life Sciences

Niagen Bioscience reported Q2 net sales of $29.8 million, missing the $30.7 million consensus, while net income collapsed to $1.0 million from $3.6 million a year ago as sales and marketing costs surged. The company launched a pharmaceutical program targeting rare genetic diseases and a telehealth platform, but the near-term financial picture is pressured by declining ingredient sales and rising expenses. The stock is trading near its 52-week low, and the earnings miss combined with a cautious outlook reinforces the negative sentiment.